whats compound semaglutide Compounded Troubling Findings in Study of

This reduction creates a vicious cycle where decreased activity leads to further muscle loss, which reduces metabolic rate, which promotes fat gain, which increases inflammation, which worsens joint discomfort and fatigue

SEP-479 oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism Recent Highlights: In May 2025, Septerna signed an exclusive global collaboration with Novo Nordisk worth up to $2.2B to co-develop oral small molecule GLP-1, GIP, and glucagon receptor agonists

Lancet 402 , 472483 (2023)

Semaglutide 2.4 mg weekly, a novel GLP- 1 receptor agonist, was the first approved treatment for obesity

FDA Resolves Semaglutide Shortage